Dr. Reddy’s Laboratories has launched Bivalirudin for Injection, 250 mg/vial, a therapeutic equivalent generic version of Angiomax (Bivalirudin) for Injection, approved by the US Food and Drug Administration (USFDA). Dr. Reddy’s Bivalirudin Injection, 250 mg/vial, are available in packages of 10 single-dose vials. Angiomax is a registered trademark of The Medicines Company.
According to IMS Health, the Angiomax brand and generic had US sales of around $198 million MAT for the most recent twelve months ending in March 2017.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
